Cancer Genetics – News and Features

Using a novel imaging technique to view cells in 3D, researchers have been able to identify two genes that control how melanoma skin cancer cells change shape – offering potential drug targets to prevent the cancer from spreading.

A new UNSW-led international study, published today in Nature Geoscience, assessed the levels of PFAS contamination in surface and ground water around the globe.

Soft tissue sarcomas are rare and difficult to treat. Machine-learning tools designed at Stanford Medicine uncover distinct cellular communities that correlate with prognosis, immunotherapy success.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working.

E-cigarette users with a limited smoking history experience similar DNA changes to specific cheek cells as smokers, finds a new study led by researchers at UCL and University of Innsbruck.

Scientists at the Massachusetts Institute of Technology have developed a rapid gene-editing screen to explore the effects of cancer mutations.

Researchers have found a new way to potentially treat one of the most common forms of acute lymphoblastic leukaemia. The study was able to kill leukaemia cells in the lab and stop cancer cells from growing.

Researchers from the Johns Hopkins Kimmel Cancer Center have developed a machine-learning approach that identifies these sequences in both tumor DNA and cell-free DNA (cfDNA) that are shed into the blood.

Trabectedin, a promising drug derived from the sea squirt Ecteinascidia turbinata, has shown potential in combating cancers resistant to conventional treatments. However, its precise mechanism of action has remained elusive—until now.